Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 34, Issue 5, 2016, Pages 540-546

  Morabito, Nunziata ^a   Catalano, Antonino ^a   Gaudio, Agostino ^b   Morini, Elisabetta ^a   Bruno, Lucia Maria ^a   Basile, Giorgio ^a   Tsiantouli, Eleni ^a   Bellone, Federica ^a   Agostino, Rita Maria ^c   Piraino, Basilia ^a   La Rosa, Maria Angela ^a   Salpietro, Carmelo ^a   Lasco, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

DKK 1; Osteoporosis; Sclerostin; Strontium ranelate; Thalassemia

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; CLODRONIC ACID; DICKKOPF 1 PROTEIN; NERIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; SCLEROSTIN; SOMATOMEDIN C; STRONTIUM RANELATE; TRANSCRIPTION FACTOR PAX5; VITAMIN D; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; GENETIC MARKER; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN; THIOPHENE DERIVATIVE;

ADULT; ANGINA PECTORIS; ARTICLE; BACKACHE; BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; FEMALE; FEMORAL NECK; HUMAN; HYPERTENSION; LUMBAR SPINE; NAUSEA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA MAJOR; VENOUS THROMBOEMBOLISM; VISUAL ANALOG SCALE; BETA THALASSEMIA; BLOOD; BONE REMODELING; COMPLICATION; DRUG EFFECTS; GENETIC MARKER; METABOLISM;

ADULT; BETA-THALASSEMIA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; FEMALE; GENETIC MARKERS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOPOROSIS; THIOPHENES;

EID: 84937893353     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-015-0689-8     Document Type: Article

References (37)

1. Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC, Paul E, Bowden DK, Strauss BJ, Milat F (2014) Thalassemia bone disease: a 19 year longitudinal analysis. J Bone Miner Res 29:2468–2473
2. Ruggiero L, De Sanctis V (1998) Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients. J Pediatr Endocrinol Metab 11:773–778
3. Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N (2002) Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 25:338–344
4. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722–727
5. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88:3966–3972
6. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, Franchina F, Maisano D, La Rosa M, Plota M, Crifò A, Meo A, Frisina N (2007) The “lively” cytokines network in beta-Thalassemia Major-related osteoporosis. Bone 40:1588–1594
7. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with β-thalassemia major. Osteoporos Int 12:570–575
8. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644–649
9. Giusti A (2014) Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab 32:606–615
10. Voskaridou E, Terpos E (2008) Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev 6:86–93
11. Rossini M, Gatti D, Adami S (2013) Involvement of WNT/b-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121–132
12. Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A (2013) Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 98:1911–1915
13. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94:725–728
14. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44:909–913
15. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski J, Spector T, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–46825
16. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822
17. Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98:592–601
18. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ (1996) The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517–523
19. Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, Tsouderos Y (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607–615
20. Marie PJ, Ammann P, Boivin G, Rey C (2001) Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121–129
21. Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129–138
22. Marie PJ, Felsenberg D, Brandi ML (2011) How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 22:1659–1667
23. Stepan JJ (2013) Strontium ranelate: in search for the mechanism of action. J Bone Miner Metab 31:606–612
24. Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R (2007) Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22:1419–1425
25. Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C (2012) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23:1115–1122
26. Rybchyn MS, Slater M, Conigrave AD, Mason RS (2011) An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J Biol Chem 286:23771–23779
27. Gulhan I, Bilgili S, Gunaydin R, Gulhan S, Posaci C (2008) The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study. Arch Gynecol Obstet 278:437–441
28. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 843:1–129
29. Catalano A, Morabito N, Basile G, Fusco S, Castagna G, Reitano F, Albanese RC, Lasco A (2013) Fracture risk assessment in postmenopausal women referred to an Italian center for osteoporosis: a single day experience in Messina. Clin Cases Miner Bone Metab 10:191–194
30. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C (2002) Prevention of early postmenopausal bone loss by strontium ranelate: the randomised, 2 year, double masked, dose-ranging, placebo-controlled PREVOS study. Osteoporos Int 13:925–931
31. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Neilsen S, de Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis–a 2 year randomised placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066
32. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY (2007) Relation between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076–3081
33. Doyard M, Fatih N, Monnier A, Island ML, Aubry M, Leroyer P, Bouvet R, Chalès G, Mosser J, Loréal O, Guggenbuhl P (2012) Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. Osteoporos Int 23:2435–2445
34. Middleton ET, Steel SA, Aye M, Doherty SM (2012) The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int 23:295–303
35. Catalano A, Morabito N, Di Stefano A, Morini M, Basile G, Faraci B, Loddo S, Ientile R, Lasco A (2015) Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate. JENI. doi:10.1007/s40618-015-0299-2
36. European medicines agency. Press release: European medicines agency recommends that protelos/osseor remain available but with further restrictions (2014) http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/02/news_detail_002031. jsp&mid = WC0b01ac58001d126
37. Marquis P, Roux C, de la Loge C, Diaz-Curiel M, Cormier C, Isaia G, Badurski J, Wark J, Meunier PJ (2008) Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 19:503–510